Fairmount Funds Boost Viridian Therapeutics Stake to 15.1%
Ticker: VRDN · Form: SC 13D/A · Filed: Apr 1, 2024 · CIK: 1590750
Sentiment: neutral
Topics: 13D-filing, ownership-change, biotech
Related Tickers: VRDN
TL;DR
Fairmount Funds now owns 15.1% of VRDN after filing an amended 13D.
AI Summary
Fairmount Funds Management LLC, along with its group members Fairmount Healthcare Fund GP LLC and Fairmount Healthcare Fund II GP LLC, has amended its Schedule 13D filing regarding Viridian Therapeutics, Inc. (VRDN). As of April 1, 2024, the group reported beneficial ownership of 10,579,560 shares, representing approximately 15.1% of the outstanding common stock. This filing indicates a change in their holdings or reporting status.
Why It Matters
This filing signals a significant ownership stake by Fairmount Funds in Viridian Therapeutics, potentially influencing the company's strategic decisions and future direction.
Risk Assessment
Risk Level: medium — Significant ownership changes by institutional investors can indicate shifts in confidence or strategy, impacting stock price volatility.
Key Numbers
- 10,579,560 — Shares Owned (Represents the total beneficial ownership by Fairmount Funds.)
- 15.1% — Ownership Stake (Indicates the significant percentage of Viridian Therapeutics' common stock held by the reporting group.)
Key Players & Entities
- Fairmount Funds Management LLC (company) — Reporting entity
- Fairmount Healthcare Fund GP LLC (company) — Group member
- Fairmount Healthcare Fund II GP LLC (company) — Group member
- Viridian Therapeutics, Inc. (company) — Subject company
- 10,579,560 (dollar_amount) — Number of shares owned
- 15.1% (dollar_amount) — Percentage of outstanding shares owned
- April 1, 2024 (date) — Filing date
FAQ
What was the previous ownership percentage reported by Fairmount Funds for Viridian Therapeutics?
The filing is an amendment (Amendment No. 5) and does not explicitly state the previous percentage, but indicates a change in holdings or reporting status as of April 1, 2024.
What is the primary business of Viridian Therapeutics, Inc.?
Viridian Therapeutics, Inc. is classified under SERVICES-MEDICAL LABORATORIES [8071] according to its SIC code.
Who are the group members filing this Schedule 13D/A?
The group members are Fairmount Healthcare Fund GP LLC and Fairmount Healthcare Fund II GP LLC, acting under the umbrella of Fairmount Funds Management LLC.
What is the business address of Viridian Therapeutics?
The business address of Viridian Therapeutics, Inc. is 221 Crescent Street, Bldg. 17, Suite 401, Waltham, MA 02453.
Has Viridian Therapeutics undergone any previous name changes?
Yes, Viridian Therapeutics was formerly known as Miragen Therapeutics, Inc. (name change on 20170213) and prior to that, Signal Genetics, Inc. (name change on 20140710).
Filing Stats: 2,068 words · 8 min read · ~7 pages · Grade level 13.1 · Accepted 2024-04-01 18:38:57
Key Financial Figures
- $0.01 — Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securiti
Filing Documents
- d818200dsc13da.htm (SC 13D/A) — 66KB
- 0001193125-24-083710.txt ( ) — 68KB
of the Statement is hereby amended and supplemented as follows
Item 3 of the Statement is hereby amended and supplemented as follows: In aggregate, the Reporting Persons have voting and dispositive power over 13,956,685 shares of Common Stock of the Company, which is comprised of (a) 1,845,813 shares of Common Stock, and (b) 12,110,872.18 (rounded to 12,110,872 shares for purposes of reporting in this Schedule 13D) shares of Common Stock issuable upon conversion of 133,191 shares of Series A Preferred Stock and 48,463 shares of Series B Preferred Stock, the conversion of which is subject to a beneficial ownership limitation of 19.99% of the outstanding Common Stock. On March 28, 2024, in connection with the wind down of Fund I, all shares of Common Stock and Series A Preferred Stock held by Fund I were transferred to Fund II. The number of shares of Common Stock and Series A Preferred Stock beneficially owned by the Reporting Persons has not changed since Amendment No. 4 to the Statement, filed on January 24, 2024. Fairmount Funds Management, Fairmount GP and Fairmount GP II do not own any shares of Common Stock, Series A Preferred Stock or Series B Preferred Stock directly. Fairmount Funds Management and Fairmount GP II are deemed to beneficially own the shares Common Stock, Series A Preferred Stock and Series B Preferred Stock held by Fund II. Fairmount Funds Management and Fairmount GP II disclaim beneficial ownership of such shares of Common Stock, Series A Preferred Stock and Series B Preferred Stock except to the extent of their pecuniary interest therein. Item5. Interest in Securities of the Company The percentages used in this Schedule 13D are calculated based upon 62,767,570 shares of Common Stock outstanding as of February 22, 2024. The Reporting Persons securities include (a) 1,845,813 shares of Common Stock and (b) 12,110,872.18 (rounded to 12,110,872 shares for purposes of reporting in this Schedule 13D) shares of Common Stock issuable upon conversion of 133,191 shares of Series A Preferred Stock and 48,4
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this statement as of April 1, 2024. FAIRMOUNT FUNDS MANAGEMENT LLC By: /s/ Peter Harwin /s/ Tomas Kiselak Peter Harwin Tomas Kiselak Managing Member Managing Member FAIRMOUNT HEALTHCARE FUND GP LLC By: /s/ Peter Harwin /s/ Tomas Kiselak Peter Harwin Tomas Kiselak Managing Member Managing Member FAIRMOUNT HEALTHCARE FUND II GP LLC By: /s/ Peter Harwin /s/ Tomas Kiselak Peter Harwin Tomas Kiselak Managing Member Managing Member